Annual CFF
$85.00 K
-$9.12 M-99.08%
December 31, 2023
Summary
- As of February 12, 2025, FATE annual cash flow from financing activities is $85.00 thousand, with the most recent change of -$9.12 million (-99.08%) on December 31, 2023.
- During the last 3 years, FATE annual CFF has fallen by -$282.75 million (-99.97%).
- FATE annual CFF is now -99.98% below its all-time high of $453.13 million, reached on December 31, 2021.
Performance
FATE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
-$1.27 M-100.00%
September 30, 2024
Summary
- As of February 12, 2025, FATE quarterly cash flow from financing activities is $0.00, with the most recent change of -$1.27 million (-100.00%) on September 30, 2024.
- Over the past year, FATE quarterly CFF has stayed the same.
- FATE quarterly CFF is now -100.00% below its all-time high of $438.05 million, reached on March 31, 2021.
Performance
FATE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$96.58 M
$0.000.00%
September 30, 2024
Summary
- As of February 12, 2025, FATE TTM cash flow from financing activities is $96.58 million, unchanged on September 30, 2024.
- Over the past year, FATE TTM CFF has increased by +$94.80 million (+5319.87%).
- FATE TTM CFF is now -86.58% below its all-time high of $719.44 million, reached on March 31, 2021.
Performance
FATE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
FATE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -99.1% | 0.0% | +5319.9% |
| 3 y3 years | -100.0% | -100.0% | +1359.6% |
| 5 y5 years | -99.9% | -100.0% | -35.7% |
FATE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.0% | at low | -100.0% | +100.0% | -78.7% | >+9999.0% |
| 5 y | 5-year | -100.0% | at low | -100.0% | +100.0% | -86.6% | >+9999.0% |
| alltime | all time | -100.0% | at low | -100.0% | +100.0% | -86.6% | +2006.5% |
Fate Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $96.58 M(0.0%) |
| Jun 2024 | - | $1.27 M(-98.7%) | $96.58 M(+1.3%) |
| Mar 2024 | - | $95.49 M(<-9900.0%) | $95.37 M(>+9900.0%) |
| Dec 2023 | $85.00 K(-99.1%) | -$180.00 K(<-9900.0%) | $85.00 K(-95.2%) |
| Sep 2023 | - | $0.00(-100.0%) | $1.78 M(-45.5%) |
| Jun 2023 | - | $58.00 K(-72.0%) | $3.27 M(-50.6%) |
| Mar 2023 | - | $207.00 K(-86.4%) | $6.62 M(-28.1%) |
| Dec 2022 | $9.21 M(-98.0%) | $1.52 M(+2.0%) | $9.21 M(-17.1%) |
| Sep 2022 | - | $1.49 M(-56.3%) | $11.11 M(-36.8%) |
| Jun 2022 | - | $3.41 M(+21.8%) | $17.56 M(-1.8%) |
| Mar 2022 | - | $2.80 M(-18.2%) | $17.88 M(-96.1%) |
| Dec 2021 | $453.13 M(+60.2%) | $3.42 M(-57.0%) | $453.13 M(-0.3%) |
| Sep 2021 | - | $7.94 M(+113.6%) | $454.62 M(+1.6%) |
| Jun 2021 | - | $3.72 M(-99.2%) | $447.61 M(-37.8%) |
| Mar 2021 | - | $438.05 M(+8821.6%) | $719.44 M(+154.4%) |
| Dec 2020 | $282.84 M(+88.6%) | $4.91 M(+428.0%) | $282.84 M(+7.1%) |
| Sep 2020 | - | $930.00 K(-99.7%) | $264.20 M(-37.8%) |
| Jun 2020 | - | $275.55 M(>+9900.0%) | $424.98 M(+183.1%) |
| Mar 2020 | - | $1.45 M(-110.6%) | $150.12 M(+0.1%) |
| Dec 2019 | $149.93 M(+6.5%) | -$13.72 M(-108.5%) | $149.93 M(-9.4%) |
| Sep 2019 | - | $161.71 M(>+9900.0%) | $165.56 M(+17.2%) |
| Jun 2019 | - | $688.00 K(-45.3%) | $141.22 M(-0.3%) |
| Mar 2019 | - | $1.26 M(-33.9%) | $141.68 M(+0.6%) |
| Dec 2018 | $140.78 M | $1.90 M(-98.6%) | $140.78 M(-22.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $137.37 M(>+9900.0%) | $182.12 M(+243.3%) |
| Jun 2018 | - | $1.16 M(+225.6%) | $53.05 M(+6.4%) |
| Mar 2018 | - | $355.00 K(-99.2%) | $49.88 M(+5.3%) |
| Dec 2017 | $47.36 M(-18.0%) | $43.24 M(+421.0%) | $47.36 M(-17.2%) |
| Sep 2017 | - | $8.30 M(-512.5%) | $57.20 M(+0.0%) |
| Jun 2017 | - | -$2.01 M(-7.3%) | $57.19 M(-0.2%) |
| Mar 2017 | - | -$2.17 M(-104.1%) | $57.29 M(-0.8%) |
| Dec 2016 | $57.74 M(+62.2%) | $53.08 M(+540.6%) | $57.74 M(+1438.0%) |
| Sep 2016 | - | $8.29 M(-534.6%) | $3.75 M(-174.1%) |
| Jun 2016 | - | -$1.91 M(+10.5%) | -$5.07 M(-115.0%) |
| Mar 2016 | - | -$1.73 M(+91.8%) | $33.80 M(-5.1%) |
| Dec 2015 | $35.60 M(+93.9%) | -$900.00 K(+68.9%) | $35.60 M(-23.4%) |
| Sep 2015 | - | -$533.00 K(-101.4%) | $46.50 M(-17.3%) |
| Jun 2015 | - | $36.96 M(>+9900.0%) | $56.26 M(+197.0%) |
| Mar 2015 | - | $75.00 K(-99.2%) | $18.94 M(+3.1%) |
| Dec 2014 | $18.37 M(-69.7%) | $10.00 M(+8.3%) | $18.37 M(-61.8%) |
| Sep 2014 | - | $9.23 M(-2706.2%) | $48.05 M(-17.1%) |
| Jun 2014 | - | -$354.00 K(-29.5%) | $58.00 M(-4.2%) |
| Mar 2014 | - | -$502.00 K(-101.3%) | $60.56 M(-0.0%) |
| Dec 2013 | $60.56 M(+263.0%) | $39.68 M(+107.0%) | $60.56 M(+190.1%) |
| Sep 2013 | - | $19.17 M(+769.1%) | $20.88 M(+1123.8%) |
| Jun 2013 | - | $2.21 M(-541.2%) | $1.71 M(-441.2%) |
| Mar 2013 | - | -$500.00 K | -$500.00 K |
| Dec 2012 | $16.68 M(+134.7%) | - | - |
| Dec 2011 | $7.11 M | - | - |
FAQ
- What is Fate Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Fate Therapeutics?
- What is Fate Therapeutics annual CFF year-on-year change?
- What is Fate Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Fate Therapeutics?
- What is Fate Therapeutics quarterly CFF year-on-year change?
- What is Fate Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Fate Therapeutics?
- What is Fate Therapeutics TTM CFF year-on-year change?
What is Fate Therapeutics annual cash flow from financing activities?
The current annual CFF of FATE is $85.00 K
What is the all time high annual CFF for Fate Therapeutics?
Fate Therapeutics all-time high annual cash flow from financing activities is $453.13 M
What is Fate Therapeutics annual CFF year-on-year change?
Over the past year, FATE annual cash flow from financing activities has changed by -$9.12 M (-99.08%)
What is Fate Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of FATE is $0.00
What is the all time high quarterly CFF for Fate Therapeutics?
Fate Therapeutics all-time high quarterly cash flow from financing activities is $438.05 M
What is Fate Therapeutics quarterly CFF year-on-year change?
Over the past year, FATE quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Fate Therapeutics TTM cash flow from financing activities?
The current TTM CFF of FATE is $96.58 M
What is the all time high TTM CFF for Fate Therapeutics?
Fate Therapeutics all-time high TTM cash flow from financing activities is $719.44 M
What is Fate Therapeutics TTM CFF year-on-year change?
Over the past year, FATE TTM cash flow from financing activities has changed by +$94.80 M (+5319.87%)